Browsing Pathways
Showing 64921 -
64930 of 605359 pathways
SMPDB ID | Pathway Name and Description | Pathway Class | Chemical Compounds | Proteins |
---|---|---|---|---|
SMP0129027View Pathway |
Abicipar Pegol Drug Metabolism |
|
||
SMP0128079View Pathway |
Abetimus Drug Metabolism |
|
||
SMP0144816View Pathway |
Abemaciclib Drug Metabolism Action Pathway |
Drug Action
|
|
|
SMP0130366View Pathway |
Abelacimab Drug Metabolism |
|
||
SMP0127747View Pathway |
Abciximab Drug Metabolism |
|
||
SMP0000265View Pathway |
Abciximab Action Pathway (old)Abciximab (also known as c7E3 Fab) is integrin (integrin alpha-IIb and integrin beta-3) receptor antagonist. Binding of abciximab to integrin receptor will block any large molecule to attach on the receptor, which will lead to block any associated signal transduction pathways.
|
Drug Action
|
|
|
SMP0121127View Pathway |
Abciximab Action PathwayAbciximab or Abcixifiban is a platelet aggregation inhibitor drug sold under the name ReoPro. It is administered intravenously, and can act to decrease platelet aggregation for up to two days after administration. Abciximab is an antigen binding fragment that targets glycoprotein IIb/IIIa receptors on the outer membrane of platelets.
In the vein, Abciximab causes a conformational change in the integrins on the surface of activated platelets. This prevents the binding of fibrinogen to these integrins, which in turn prevents the platelets from being held together by these fibrinogen fibres. The conformational change also prevents the binding of von Willebrand factor to the platelets, which also prevents aggregation and adhesion.
|
Drug Action
|
|
|
SMP0127806View Pathway |
Abatacept Drug Metabolism |
|
||
SMP0142593View Pathway |
Abarelix Drug Metabolism Action Pathway |
Drug Action
|
|
|
SMP0144801View Pathway |
Abametapir Drug Metabolism Action Pathway |
Drug Action
|
|
|
Showing 64921 -
64930 of 65005 pathways